Richardson, P. G., Kumar, S. K., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., Stoppa, A., Gimsing, P., Garderet, L., Touzeau, C., Buadi, F. K., Laubach, J. P., Cavo, M., Darif, M., Labotka, R., Berg, D., & Moreau, P. (2021). final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of clinical oncology, 39(22), 2430–2442. http://access.bl.uk/ark:/81055/vdc_100150610964.0x000029